◀ Back to PPARG
AGTR1 — PPARG
Text-mined interactions from Literome
Sugawara et al., Hypertens Res 2003
(Arteriosclerosis...) :
We previously reported that ligand activated
PPAR-gamma suppressed
angiotensin II type 1 receptor (AT1R) gene transcription in vascular smooth muscle cells ( VSMCs ) by the inhibition of Sp1 binding to the -- 58/ -- 34 GC-box related element in the AT1R gene promoter region via a protein-protein interaction ... Since both the MAP kinase pathway and CBP have recently been reported to be atherogenic, we examined their effects on
PPAR-gamma mediated
AT1R gene transcription suppression ... We observed that 1 ) PPAR-gamma mediated AT1R gene transcription suppression was augmented by treatment with the MAP kinase kinase inhibitor PD98059, while treatment with the p38 kinase inhibitor SB203580 showed no effect ; 2 ) the PPAR-gamma mediated AT1R mRNA decrease was also augmented by PD98059 treatment ; 3 ) CBP overexpression partially, but significantly, abrogated
PPAR-gamma mediated
AT1R gene transcription suppression ; and 4 ) the CBP effect was eliminated when the -- 58/ -- 34 GC-box related element was disrupted ... It is therefore speculated that : 1 ) PPAR-gamma phosphorylation by the MAP kinase pathway may attenuate PPAR-gamma mediated AT1R gene transcription suppression through the inhibition of PPAR-gamma activity ; and 2 ) CBP may enhance the activity of the remaining Sp1 on the -- 58/ -- 34 GC-box related element, resulting in a reduction in
PPAR-gamma mediated
AT1R gene transcription suppression
Benson et al., J Hypertens 2008
:
Telmisartan can also inhibit the proliferation of cells that lack angiotensin II receptors and cells treated with a PPAR gamma antagonist suggesting that the antiproliferative effects of telmisartan may involve more than just
angiotensin II receptor blockade or
activation of
PPAR gamma
Kappert et al., Hypertension 2009
(Hypertension) :
PPARgamma activation by
AT1R-blockers may translate into synergistic beneficial actions in monocytes
Yamamoto et al., Hypertension 2009
(Atherosclerosis) :
In summary, the antiproliferative effects of telmisartan in the absence of exogenously supplemented angiotensin II involve more than just
AT1 receptor blockade and do not
require activation of
PPARgamma